ES2136581B1 - Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb. - Google Patents

Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.

Info

Publication number
ES2136581B1
ES2136581B1 ES009801154A ES9801154A ES2136581B1 ES 2136581 B1 ES2136581 B1 ES 2136581B1 ES 009801154 A ES009801154 A ES 009801154A ES 9801154 A ES9801154 A ES 9801154A ES 2136581 B1 ES2136581 B1 ES 2136581B1
Authority
ES
Spain
Prior art keywords
preparation
transcription factor
derivatives
trifluorometilbenzoico
hidroxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009801154A
Other languages
English (en)
Other versions
ES2136581A1 (es
Inventor
Roca Manuel Merlos
De Arriba Alberto Fernandez
De Maria Fernando L Cavalcanti
Acosta Agusti Miralles
Crespo Mariano Sanchez
Rafanell Julian Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noucor Health SA
Original Assignee
J Uriach y Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES009801154A priority Critical patent/ES2136581B1/es
Application filed by J Uriach y Cia SA filed Critical J Uriach y Cia SA
Priority to PT99920872T priority patent/PT1082962E/pt
Priority to EP99920872A priority patent/EP1082962B1/en
Priority to AU38286/99A priority patent/AU3828699A/en
Priority to PCT/ES1999/000154 priority patent/WO1999061030A1/es
Priority to CA002332863A priority patent/CA2332863A1/en
Priority to US09/701,270 priority patent/US6414025B1/en
Priority to KR1020007013316A priority patent/KR100713601B1/ko
Priority to KR1020067026281A priority patent/KR100762156B1/ko
Priority to AT99920872T priority patent/ATE245987T1/de
Priority to EP03012255A priority patent/EP1362592A1/en
Priority to ES99920872T priority patent/ES2204129T3/es
Priority to JP2000550490A priority patent/JP2002516283A/ja
Priority to DE69910019T priority patent/DE69910019T2/de
Priority to DK99920872T priority patent/DK1082962T3/da
Priority to BR9911598-0A priority patent/BR9911598A/pt
Publication of ES2136581A1 publication Critical patent/ES2136581A1/es
Publication of ES2136581B1 publication Critical patent/ES2136581B1/es
Application granted granted Critical
Priority to NO20005981A priority patent/NO20005981L/no
Priority to US10/115,140 priority patent/US6610745B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La invención se refiere a la utilización de derivados del ácido 2-hidroxi-4-trifluorometilbenzoico para la preparación de medicamentos útiles para inhibir la activación del factor transcripción NF-kB. La invención se refiere también a la utilización de derivados del ácido 2-hidroxi-4- trifluorometilbenzoico para la preparación de medicamentos destinados al tratamiento o prevención de patologías mediadas por la activación de NF-kB y/o la expresión de sus genes dependientes en mamíferos, incluido el hombre.
ES009801154A 1998-05-27 1998-05-27 Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb. Expired - Fee Related ES2136581B1 (es)

Priority Applications (18)

Application Number Priority Date Filing Date Title
ES009801154A ES2136581B1 (es) 1998-05-27 1998-05-27 Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
JP2000550490A JP2002516283A (ja) 1998-05-27 1999-05-26 核転写因子ＮＦ−κＢの活性化の阻害剤としての２−ヒドロキシ−４−トリフルオロメチル安息香酸誘導体の使用
EP99920872A EP1082962B1 (en) 1998-05-27 1999-05-26 Utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factors nf-(k)b
PCT/ES1999/000154 WO1999061030A1 (es) 1998-05-27 1999-05-26 USO DE DERIVADOS DEL ACIDO 2-HIDROXI-4-TRIFLUOROMETILBENZOICO COMO INHIBIDORES DE LA ACTIVACION DEL FACTOR DE TRANSCRIPCION NUCLEAR NF-λB
CA002332863A CA2332863A1 (en) 1998-05-27 1999-05-26 Use of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor nf-.kappa.b
US09/701,270 US6414025B1 (en) 1998-05-27 1999-05-26 Utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factors NF-κβ
KR1020007013316A KR100713601B1 (ko) 1998-05-27 1999-05-26 핵전사인자 ＮＦ-κＢ의 활성화의 억제제로서의2-히드록시-4-트리플루오로메틸벤조산 유도체의 용도
KR1020067026281A KR100762156B1 (ko) 1998-05-27 1999-05-26 핵전사인자 ＮＦ-κＢ의 활성화의 억제제로서의2-히드록시-4-트리플루오로메틸벤조산 유도체의 용도
DE69910019T DE69910019T2 (de) 1998-05-27 1999-05-26 Verwendung von derivaten der 2-hydroxy-4-trifluormethylbenzoe säure als hemmer der aktivierung des nuklearischen transkriptionsfaktors nf-(k)b
EP03012255A EP1362592A1 (en) 1998-05-27 1999-05-26 Use of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-kB
PT99920872T PT1082962E (pt) 1998-05-27 1999-05-26 Utilizacao de derivados do acido 2-hidroxi-4-trifluorometilbenzoico como inibidores da activacao dos factores de transcricao nucleares nf-(k)b
AU38286/99A AU3828699A (en) 1998-05-27 1999-05-26 Utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitorsof the activation of the nuclear transcription factors nf-Kappa
AT99920872T ATE245987T1 (de) 1998-05-27 1999-05-26 Verwendung von derivaten der 2-hydroxy-4- trifluormethylbenzoe säure als hemmer der aktivierung des nuklearischen transkriptionsfaktors nf-(k)b
DK99920872T DK1082962T3 (da) 1998-05-27 1999-05-26 Anvendelse af 2-hydroxy-4-trifluormethylbenzoesyrederivater som inhibitorer af aktiveringen af de nukleare transskriptionsfaktorer NF-(K)B
BR9911598-0A BR9911598A (pt) 1998-05-27 1999-05-26 Uso de derivados do ácido 2-hidróxi-4-trifluormetilbenzóico como inibidores da ativação do fator de transcrição nuclear nf-kb
ES99920872T ES2204129T3 (es) 1998-05-27 1999-05-26 Uso de derivados del acido 2-hidroxi-4-trifluorometilbenzoico como inhibidores de la activacion del factor de transcripcion nuclear nf- (k)b.
NO20005981A NO20005981L (no) 1998-05-27 2000-11-27 Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- <kappa>B
US10/115,140 US6610745B2 (en) 1998-05-27 2002-04-04 Use of 2-hydroxy-4-trifluoromethyl-benzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-KS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009801154A ES2136581B1 (es) 1998-05-27 1998-05-27 Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.

Publications (2)

Publication Number Publication Date
ES2136581A1 ES2136581A1 (es) 1999-11-16
ES2136581B1 true ES2136581B1 (es) 2000-09-16

Family

ID=8304002

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009801154A Expired - Fee Related ES2136581B1 (es) 1998-05-27 1998-05-27 Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
ES99920872T Expired - Lifetime ES2204129T3 (es) 1998-05-27 1999-05-26 Uso de derivados del acido 2-hidroxi-4-trifluorometilbenzoico como inhibidores de la activacion del factor de transcripcion nuclear nf- (k)b.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99920872T Expired - Lifetime ES2204129T3 (es) 1998-05-27 1999-05-26 Uso de derivados del acido 2-hidroxi-4-trifluorometilbenzoico como inhibidores de la activacion del factor de transcripcion nuclear nf- (k)b.

Country Status (14)

Country Link
US (2) US6414025B1 (es)
EP (2) EP1082962B1 (es)
JP (1) JP2002516283A (es)
KR (2) KR100762156B1 (es)
AT (1) ATE245987T1 (es)
AU (1) AU3828699A (es)
BR (1) BR9911598A (es)
CA (1) CA2332863A1 (es)
DE (1) DE69910019T2 (es)
DK (1) DK1082962T3 (es)
ES (2) ES2136581B1 (es)
NO (1) NO20005981L (es)
PT (1) PT1082962E (es)
WO (1) WO1999061030A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2154242B1 (es) * 1999-09-03 2001-10-16 Uriach & Cia Sa J Nuevos sistemas polimericos biocompatibles portadores de triflusal o htb.
US20040101488A1 (en) * 2000-03-24 2004-05-27 Balaram Ghosh Method for the prevention of septic shock lethality using curcumin
ES2190373B1 (es) * 2001-12-07 2004-10-16 J. URIACH &amp; CIA, S.A. Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.
JP2006502183A (ja) 2002-09-20 2006-01-19 アルコン，インコーポレイテッド ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用
CA2725008C (en) 2008-05-28 2017-09-05 Validus Biopharma, Inc. Non-hormonal steroid modulators of nf-.kappa.b for treatment of disease
EP2408454A2 (en) 2009-03-18 2012-01-25 Resverlogix Corp. Novel anti-inflammatory agents
US9198921B2 (en) 2010-04-05 2015-12-01 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
CN103665012B (zh) * 2013-12-06 2016-06-22 辽宁师范大学 新型三氟柳无机药物化合物及合成方法
WO2017004205A1 (en) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
US20180016314A1 (en) * 2016-07-12 2018-01-18 Children's Hospital Medical Center Treatment of disease via transcription factor modulation
KR101975603B1 (ko) 2018-09-14 2019-08-28 이영문 조력 발전장치
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096252A (en) * 1976-06-10 1978-06-20 J. Uriach & Cia S.A. 4-Trifluoromethylbenzoic acid derivatives as thromboembolic agents
IT1276071B1 (it) * 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria

Also Published As

Publication number Publication date
KR100713601B1 (ko) 2007-05-02
KR20010052404A (ko) 2001-06-25
DE69910019T2 (de) 2004-05-06
DE69910019D1 (de) 2003-09-04
CA2332863A1 (en) 1999-12-02
PT1082962E (pt) 2003-11-28
NO20005981D0 (no) 2000-11-27
KR100762156B1 (ko) 2007-10-04
US20030032630A1 (en) 2003-02-13
EP1362592A1 (en) 2003-11-19
KR20070006943A (ko) 2007-01-11
NO20005981L (no) 2000-12-12
DK1082962T3 (da) 2003-11-24
AU3828699A (en) 1999-12-13
BR9911598A (pt) 2001-02-13
ES2204129T3 (es) 2004-04-16
US6414025B1 (en) 2002-07-02
US6610745B2 (en) 2003-08-26
ES2136581A1 (es) 1999-11-16
EP1082962A1 (en) 2001-03-14
JP2002516283A (ja) 2002-06-04
WO1999061030A1 (es) 1999-12-02
EP1082962B1 (en) 2003-07-30
ATE245987T1 (de) 2003-08-15

Similar Documents

Publication Publication Date Title
CY1120313T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες
BR9611802A (pt) Composições farmacêuticas
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
ES2136581B1 (es) Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
MX9205937A (es) Sistema de penetracion incrementada de la piel para surtido topico mejorado de farmacos
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
BR0107246A (pt) Agentes diazabicìclicos ativos no sistema nervoso central
BR9910583A (pt) Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
ES2161785T3 (es) Emplasto para el tratamiento de micosis ungulares.
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BRPI0411699A (pt) compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
TR199903053T2 (xx) Benzimidazol t�revleri.
BRPI0418270A (pt) métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
EP1157698A3 (en) Treatment of inflammatory diseases with oxypurine nucleosides
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
BR9608255A (pt) Sistema terapéutico transdérmico (stt) para a administração de testosterona
AR023781A1 (es) Formulaciones farmaceuticas
NO20014081L (no) Anvendelse av tianeptin i produksjonen av medikamenter til behandling av nevrodegenerative patologier

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19991116

Kind code of ref document: A1

Effective date: 19991116

FD1A Patent lapsed

Effective date: 20050528